Main description:

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index. Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.

Contents:

VOLUME I: DEFINING THE RIGHT ANTIBODY COMPOSITION Therapeutic Antibodies - From Past to Future Stefan Dubel PART 1: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection Strategies I: Monoclonal Antibodies Gerhard Moldenhauer Selection Strategies II: Antibody Phage Display Michael Hust, Andre Frenzel, Florian Tomszak, Jonas Koller Transgenic Animals Derived by DNA Microinjection Marianne Bruggemann, Michael J. Osborn, Biao Moa, Suzanne Avis, Ignacio Anegon, Roland Bulow Molecular Engineering I: Humanisation Strategies Jose Saldanha Antibody Affinity Andre Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, Larry Green Molecular Engineering III: Fc Thomas Valerius, Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner Glycosylation of Antibody Molecules Roy Jefferis Bioinformatics Tools for Analysis of Antibodies Andrew C. R. Martin, James Allen How to use IMGT for Therapeutic Antibody Engineering Marie-Paul Lefranc PART 2: MODIFIED ANTIBODIES Bispecific Antibodies Roland E. Kontermann, Dafne Muller Single Domain Antibodies: An Overview Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, B. Hamilton Antibody-Drug Conjugates (ADCs): New Frontier in Cancer Therapeutics Ravi Chari, Rajeeva Singh, John M. Lambert Antibody Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins Jurgen Krauss, Athanasios Mavratzas, Michaela A. E. Arndt, Stefan Kiesgen PART 3: EMERGING TECHNOLOGIES Emerging Technologies for Antibody Selection Mike Taussig, Mingyue He Anti-idiotypic Antibodies Alejandro Lopez-Requena, Oscar Roberto Burrone, Rolando Perez Non-antibody Scaffolds as Alternative Therapeutic Agents Arne Skerra, Markus Fiedler Antibody Directed Enzyme Prodrug Therapy (ADEPT) Surinder K. Sharma, Kerry A. Chester, Kenneth D. Bagshawe Engineered Antibody Domains as Candidate Therapeutics Weizao Chen, Ponraj Prabakaran, Dimiter S. Dimitrov Chimeric Antigen Receptors - "CARs" Thomas Schirrmann, Ulf Petrausch Emerging Alternative Production Systems Thomas Jostock, Benjamin Sommer, Holger Laux, Andre Frenzel VOLUME II: CLINICAL DEVELOPMENT OF ANTIBODIES PART 4: THE WAY INTO THE CLINIC Process Development and Manufacturing of Therapeutic Antibodies Hitto Kaufmann, Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser The Immunogenicity of Therapeutic Antibodies Melody Sauerborn Biosimilar Monoclonal Antibodies Susanne D. Pippig, Carsten Brockmeyer, Robert E. Zoubek Patent Issues Relating to Therapeutic Antibodies Michael Braunagel, Barbara Rigby, Deborah Owen PART 5: THERAPEUTIC ANTIBODY PIPELINE Monoclonal Antibodies in Phase III Clinical Trials Peter Markus Deckert, Ulf Petrausch Antibodies in Early Phase Clinical Studies: Cancer Therapy Anthony Olszanski, Matthew Zibelman, Hossein Borghaei Targeting Angiogenesis by Therapeutic Antibodies Thomas Effert, Onat Kadioglu, Ean Jeong Seo Antibodies in Phase 3: Immunological Disorders Penelope Ward, Mark Bodmer Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders Frank Brennan MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders Frank Brennan T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan B Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan mAbs Targeting Apoptosis, Angiogenesis Inhibitors and other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders Frank Brennan Antibodies in Clinical Study: Infectious Diseases Guillaume Descoubeaux Immunotherapeutics for Neurological Disorders Anne Messer, Kevin Manley, Cynthia A. Lemere PART 6: GAINING MARKETING APPROVAL Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy Marjorie A. Shapiro, Patrick G. Swann, Stacey Ricci Regulatory Review: Clinical to Market Transition Gabriele Dallmann Monoclonal antibody nomenclature for clinical studies (USA) Stephanie Shubat VOLUME III: APPROVED THERAPEUTIC ANTIBODIES PART 7: APPROVED THERAPEUTIC ANTIBODIES Oligoclonal and Polyclonal Antibody Preparations Mark C. Glassy, Rishab K. Gupta Adalimumab (Humira) Janice Reichert Alemtuzumab (Lemtrada, MabCampath) Janice Reichert, Thomas Elter, Michael Hallek Basiliximab and Daclizumab Nasimul Ahsan, Burcin Taner, Nadim Mahmud Belimumab (Benlysta) David P. D'Cruz, Pamela M.K. Lutalo, Natasha Jordan, Thi-Sau Migone Brentuximab vedotin (Adcetris) Neils van de Donk Canakinumab (ILARIS) Hermann Gram Catumaxomab (Removab) - Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination Horst Lindhofer, M. Stanglmaier, R. Buhmann, M. Jager, D. Klunker, P. Ruf, J. Hess Cetuximab (Erbitux) Sonja Wilke, Michael Hust Denosumab (Prolia) Torsten Meyer Efalizumab (Raptiva) Karlheinz Schmitt-Rau Calicheamycin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin Martin Gramatzki, Matthias Peipp Golimumab (Simponi) Janice Reichert, Sohini Mazumdar Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Karin Hohloch, Bjorn Chapuy, Lorenz Trumper Infliximab (Remicade) Christian Antoni Ipilimumab (Yervoy) Javier Puente, Teresa Alonso Gordoa, Eduardo Diaz-Rubio Muromonab-CD3 (Orthoclone OKT3) Janice Reichert, Harald Becker Nimotuzumab: A Humanized Anti-EGFR Antibody Tania Crombet Obinutuzumab Christian Klein, Marina Bacac, Pablo Umana, Michael Wenger VOLUME IV: APPROVED THERAPEUTIC ANTIBODIES AND IN VIVO DIAGNOSTICS Ofatumumab: A Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity Ronald P. Taylor, Margaret A. Lindorfer, Joost Bakker, Paul Parren Omalizumab (Xolair) - Anti-Immunoglobulin E Treatment in Allergic Diseases Klaus Kroegel, Martin Foerster Palivizumab Louis Bont Panitumumab (Vectibix) - A Treatment for Metastatic Colorectal Cancer Jonas Kugler Pertuzumab (Perjeta) Jose Angel Garcia-Saenz, Fernando Moreno Anton, Coralia Bueno Muino Ranibizumab (Lucentis): A New Anti-angiogenic Treatment in Ophthalmology Nicolas Leveziel, Marc Ohresser, Gilles Paintaud Raxibacumab - Human Monoclonal Antibody Against Anthrax Toxin Sally Bolmer, Thi-Sau Migone Rituximab (Rituxan) Stefan Dubel, Axel Boehnke, Michael Wenger Tocilizumab (Actemra) Graeme Jones Trastuzumab (Herceptin) and Ado-Trastuzumab Emtansine (T-DM1) M. H. Ruhe Chowdhury, Paul Ellis Ustekinumab (Stelara) Stefan Dubel, Oya Cingoz, Janice Reichert Abciximab, Bevacizumab, Certolizumab pegol, Eculizumab, Natalizumab Janice Reichert Itolizumab (Alzumab), Mogamulizumab (Poteligeo) and Tositumomab (Bexxar) Stefan Dubel PART 8: IN VIVO DIAGNOSTICS Radiolabeled Antibodies for Diagnostic Imaging Christopher J. Palestro Appendix Index